The Potential Role of Purinergic Signaling in Cancer Therapy: Perspectives on Anti-CD73 Strategies for Prostate Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Oct 2

PMID 39355246

Authors

Carla Fernanda Furtado Gardani

Fernando Mendonca Diz

Luisa Brandalise Donde

Liliana Rockenbach

Stefan Laufer

Fernanda Bueno Morrone

Affiliations

Soon will be listed here.

Abstract

Purines and pyrimidines are signaling molecules in the tumor microenvironment that affect cancer immunity. The purinergic signaling pathways have been shown to play an important role in the development and progression of cancer. CD39 and CD73 are ectonucleotidases responsible for breaking down ATP or ADP into adenosine, which regulates immunosuppression in various types of cancer. These enzymes have been studied as a potential therapeutic target in immunotherapy, and recent research suggests a correlation between ectonucleotidases and clinical outcomes in cancer.Prostate cancer is the most diagnosed cancer in men, after non-melanoma skin tumors, and is the second leading cause of death in men in the world. Despite having long survival periods, patients often receive excessive or insufficient treatment. Within this complex landscape, the adenosine/CD73 pathway plays a crucial role. Therefore, this review aims to highlight new findings on the potential role of purinergic signaling in cancer treatment and emphasizes the importance of anti-CD73 as a pharmacological strategy for prostate cancer therapy.

Citing Articles

Reduction of Prostate Cancer Risk: Role of Frequent Ejaculation-Associated Mechanisms.

Hassan M, Flanagan T, Eshaq A, Altamimi O, Altalag H, Alsharif M Cancers (Basel). 2025; 17(5).

PMID: 40075690 PMC: 11898507. DOI: 10.3390/cancers17050843.

Apoptotic Vesicles Attenuate Acute Lung Injury CD73-Mediated Inhibition of Platelet Activation and NETosis.

Tan L, Zhang C, Kou X, Zhao L, Wu D, Li J Int J Nanomedicine. 2025; 20():91-107.

PMID: 39802376 PMC: 11717653. DOI: 10.2147/IJN.S485012.

References

McAllister S, Weinberg R . Tumor-host interactions: a far-reaching relationship. J Clin Oncol. 2010; 28(26):4022-8. DOI: 10.1200/JCO.2010.28.4257. View

Chen S, Wainwright D, Wu J, Wan Y, Matei D, Zhang Y . CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy. 2019; 11(11):983-997. PMC: 6609898. DOI: 10.2217/imt-2018-0200. View

Friedenreich C, Ryder-Burbidge C, McNeil J . Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms. Mol Oncol. 2020; 15(3):790-800. PMC: 7931121. DOI: 10.1002/1878-0261.12772. View

Wang J, Matosevic S . Adenosinergic signaling as a target for natural killer cell immunotherapy. J Mol Med (Berl). 2018; 96(9):903-913. DOI: 10.1007/s00109-018-1679-9. View

Morrone F, Vargas P, Rockenbach L, Scheffel T . P2Y Purinergic Receptor and Brain Tumors: Implications on Glioma Microenvironment. Molecules. 2021; 26(20). PMC: 8540665. DOI: 10.3390/molecules26206146. View

Wolf A, Wender R, Etzioni R, Thompson I, DAmico A, Volk R . American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60(2):70-98. DOI: 10.3322/caac.20066. View

Guo S, Han F, Zhu W . CD39 - A bright target for cancer immunotherapy. Biomed Pharmacother. 2022; 151:113066. DOI: 10.1016/j.biopha.2022.113066. View

Di Virgilio F, Adinolfi E . Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2016; 36(3):293-303. PMC: 5269532. DOI: 10.1038/onc.2016.206. View

Liu Y, Li Z, Zhao X, Xiao J, Bi J, Li X . Review immune response of targeting CD39 in cancer. Biomark Res. 2023; 11(1):63. PMC: 10249319. DOI: 10.1186/s40364-023-00500-w. View

10.

Lim E, Bendell J, Falchook G, Bauer T, Drake C, Choe J . Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clin Cancer Res. 2022; 28(22):4871-4884. PMC: 9660540. DOI: 10.1158/1078-0432.CCR-22-0612. View

11.

Scheffel T, Grave N, Vargas P, Diz F, Rockenbach L, Morrone F . Immunosuppression in Gliomas PD-1/PD-L1 Axis and Adenosine Pathway. Front Oncol. 2021; 10:617385. PMC: 7919594. DOI: 10.3389/fonc.2020.617385. View

12.

Gardani C, Pedrazza E, Paz V, Zanirati G, Da Costa J, Andrejew R . Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer. Pharmaceuticals (Basel). 2023; 16(11). PMC: 10675019. DOI: 10.3390/ph16111619. View

13.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

14.

Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L . Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007; 67(7):2912-5. DOI: 10.1158/0008-5472.CAN-07-0520. View

15.

Burnstock G . Purinergic signalling. Br J Pharmacol. 2006; 147 Suppl 1:S172-81. PMC: 1760723. DOI: 10.1038/sj.bjp.0706429. View

16.

Baghbani E, Noorolyai S, Shanehbandi D, Mokhtarzadeh A, Aghebati-Maleki L, Shahgoli V . Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. Life Sci. 2021; 282:119826. DOI: 10.1016/j.lfs.2021.119826. View

17.

Bastid J, Regairaz A, Bonnefoy N, Dejou C, Giustiniani J, Laheurte C . Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res. 2014; 3(3):254-65. DOI: 10.1158/2326-6066.CIR-14-0018. View

18.

Zimmermann H, Zebisch M, Strater N . Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal. 2012; 8(3):437-502. PMC: 3360096. DOI: 10.1007/s11302-012-9309-4. View

19.

Morello S, Capone M, Sorrentino C, Giannarelli D, Madonna G, Mallardo D . Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J Transl Med. 2017; 15(1):244. PMC: 5716054. DOI: 10.1186/s12967-017-1348-8. View

20.

Beavis P, Milenkovski N, Henderson M, John L, Allard B, Loi S . Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunol Res. 2015; 3(5):506-17. DOI: 10.1158/2326-6066.CIR-14-0211. View